DDInter875 DDInter849
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Guselkumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Guselkumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rivaroxaban
Guselkumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Guselkumab {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Guselkumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Guselkumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Guselkumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Guselkumab may lead to a major life threatening interaction when taken with Upadacitinib